Separase Loss of Function Cooperates with the Loss of p53 in the Initiation and Progression of T- and B-Cell Lymphoma, Leukemia and Aneuploidy in Mice by Mukherjee, Malini et al.
Separase Loss of Function Cooperates with the Loss of
p53 in the Initiation and Progression of T- and B-Cell
Lymphoma, Leukemia and Aneuploidy in Mice
Malini Mukherjee
1, Gouqing Ge
1, Nenggang Zhang
1, Eryong Huang
1, Lanelle V. Nakamura
1, Marissa
Minor
1, Viacheslav Fofanov
3, Pullivarthi H. Rao
1, Alan Herron
2, Debananda Pati
1*
1Department of Pediatric Hematology/Oncology, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, Texas, United States of America, 2Department of
Pathology and Immunology and Center for Comparative Medicine, Baylor College of Medicine, Houston, Texas, United States of America, 3Eureka GenomicsH, Corp,
Houston, Texas, United States of America
Abstract
Background: Cohesin protease Separase plays a key role in faithful segregation of sister chromatids by cleaving the cohesin
complex at the metaphase to anaphase transition. Homozygous deletion of ESPL1 gene that encodes Separase protein
results in embryonic lethality in mice and Separase overexpression lead to aneuploidy and tumorigenesis. However, the
effect of Separase haploinsufficiency has not been thoroughly investigated.
Methodology/Principal Findings: Here we examined the effect of ESPL1 heterozygosity using a hypomorphic mouse model
that has reduced germline Separase activity. We report that while ESPL1 mutant (ESPL1
+/hyp) mice have a normal phenotype,
in the absence of p53, these mice develop spontaneous T- and B-cell lymphomas, and leukemia with a significantly
shortened latency as compared to p53 null mice. The ESPL1 hypomorphic, p53 heterozygous transgenic mice (ESPL1
+/hyp,
p53
+/2) also show a significantly reduced life span with an altered tumor spectrum of carcinomas and sarcomas compared
to p53
+/2 mice alone. Furthermore, ESPL1
+/hyp, p53
2/2 mice display significantly higher levels of genetic instability and
aneuploidy in normal cells, as indicated by the abnormal metaphase counts and SKY analysis of primary splenocytes.
Conclusions/Significance: Our results indicate that reduced levels of Separase act synergistically with loss of p53 in the
initiation and progression of B- and T- cell lymphomas, which is aided by increased chromosomal missegregation and
accumulation of genomic instability. ESPL1
+/hyp, p53
2/2 mice provide a new animal model for mechanistic study of
aggressive lymphoma and also for preclinical evaluation of new agents for its therapy.
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Introduction
An evolutionarily conserved complex of proteins called cohesin
is responsible for holding sister chromatids together prior to
anaphase to prevent premature separation of sister chromosomes
[1,2]. At the onset of anaphase, cohesin subunit Rad21 is cleaved
by the endopeptidase Separase which then allows sister chromatid
separation and normal cell division to progress. Early cleavage of
Rad21 by Separase can lead to abnormal accumulation of
chromosomes and this is prevented by the tight regulation of
Separase by its inhibitory chaperone Securin [3–6]. Phosphory-
lation of Securin by the Anaphase Promoting Complex/Cyclo-
some (APC/C) results in its ubiquitin-mediated degradation and
release of free Separase which then cleaves cohesin Rad21 [7–11].
Phosphorylation of Separase by Cyclin B/Cdk1 also negatively
regulates its activity and prevents premature Rad21 cleavage
[12,13]. It is therefore not surprising that the premature cleavage
of the cohesin complex by early activation of Separase or by
increased Separase activity results in the accumulation of
abnormal chromosome number leading to aneuploidy. For
example, increased expression of Separase in the mouse mammary
epithelium results in the rapid accumulation of aneuploidy
resulting in subsequent tumorigenesis [14,15]. Also, overexpres-
sion of Separase has been detected in several human tumors,
including breast and prostate tumors and osteosarcoma [16]
suggesting a direct or indirect role of Separase in the etiology of
human cancers. Furthermore, loss of catalytic activity of Separase
caused by a truncating mutation in the gene has been shown to
cause increased epithelial tumors along with a significant increase
in genetic instability in a zebra fish model [17]. Correlative studies
have reported the loss or decrease in Separase expression levels
caused by somatic mutations in the ESPL1 gene in human lung
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COSMIC database; [18]). Despite implications from the above
mentioned studies that loss of Separase may have a role in the
initiation and/or progression of cancer, the direct effects of loss of
Separase if any on carcinogenesis have not been well studied.
SiRNA mediated knockdown of Separase in HeLa cells and
Separase deficient mouse embryonic fibroblasts results in
polyploidy [10,19]. Separase knockout mice are embryonic
lethal [20,21] and no significant phenotype in Separase
heterozygous mice have been reported to date. However, given
the critical role of Separase in chromosomal segregation, it is
likely that either the loss or gain of functional mutations of
ESPL1 can have serious consequences and may also lead to
tumorigenesis.
Human cancer progresses as a multi-step process with cooper-
ation between loss of key tumor suppressor genes as well as
activationofoncogenes [22,23].Therefore,looking atthecombined
effect of losses or gains in several genes to see if that promotes or
accelerates tumorigenesis has been a well accepted strategy in the
development of mouse models of human cancer. p53 is one of the
most frequently used candidates that have been shown to
collaborate with other genetic mutations to promote initiation and
progression of several malignancies [24–28]. Loss of p53 is an
extremely frequent event in many human solid tumors and is also
detected fairly often in hematopoietic tumors (http://www-p53.
iarc.fr/GraphSTAT.asp?TypeGraph=TumorPrevalence). Indivi-
duals born with a single mutated copy of p53 have the cancer pre-
disposing Li-Fraumeni syndrome that pre-disposes them to the
development of many different cancers in their life time [29,30].
Many mouse models have been established over the past several
years to study the role of gain or loss of p53 function in various cell
types [31–34]. These studies showed that mice homozygous for
p53 develop a variety of spontaneous neoplasms and predomi-
nantly thymic lymphoblastic lymphomas with latency from four to
six months, depending on the genetic background of the mice.
Mice heterozygous for p53 also develop a variety of neoplasms,
specifically osteosarcomas and soft tissue carcinomas, although
with a longer latency of eight months and more [31]. Tumor
latencies in these mice are also greatly influenced by the strain
background. These results suggest that loss of p53 is an event that
allows other stochastic mutations to accumulate within the cell
resulting in cancer formation. So rather than being a ‘‘causal’’
event, loss of p53 is an ‘‘enabling’’ event for cancer initiation and
progression. Given the already established premises that loss of
p53 leads to a reduction in apoptosis and DNA damage repair
mechanisms, and also the putative role of Separase in chromo-
somal segregation [35] and DNA damage repair pathways [19,36],
it was our hypothesis that loss of function mutations of both of
these genes can collaborate in initiating and promoting malignant
transformation in multiple cell types.
In an effort to understand the consequences of reduction of
Separase levels in vivo both alone and in cooperation with p53 loss,
we have developed and characterized Separase hypomorphic mice
(referred to here as ESPL1
+/hyp mice) with reduced Separase
protein level, in the absence and presence of p53. We report here
that mice heterozygous for the Separase hypomorph are viable in
a C57Bl/6J background but the compound Separase hypomor-
phic, p53 homozygous mice (ESPL1
+/hyp, p53
2/2) in the same
genetic background have a significantly increased rate of
tumorigenesis, shortened life span and mortality reaching 100%
within 4–6 months of life. ESPL1
+/hyp, p53
2/2mice develop
aggressive mixed T- and B-cell lymphomas along with leukemia
involving the blood and bone marrow. Interestingly, normal
tissues in these mice display significantly increased aneuploidy and
chromosomal aberrations suggesting aneuploidy as precursor of
tumorigenesis. These findings collectively indicate that reduction
in Separase levels cooperate with loss of p53 in the generation of
aggressive T- and B- cell lymphomas and leukemia in mice
through increased aneuploidy and accumulation of multiple
chromosomal aberrations.
Results
1. Generation of Separase hypomorphic mice
To evaluate the effects of reduced expression of Separase,
Separase hypomorphic mice were generated in a C57BL/6
background using the Baygenomics genetrap clone XL058. In
this clone the gene trap insertion selectively disrupts the last but
one exon (exon 30) of the ESPL1 gene resulting in effective
disruption of the C-terminal 105 amino acids encoding a major
part of the peptidase domain of the Separase protein (Figure 1, A).
Homozygous XL058 ESPL1 mutants were embryonic lethal at
E6.5 days, confirming the previous report for an essential role of
Separase [20,21]. ESPL1
+/hyp mice were born normally with no
apparent abnormality or disease phenotype over two years of
observations. Due to lack of a suitable C-terminal Separase
antibody, Separase expression in the hypomorphic mice was
carried out using an N-terminal antibody. Analysis of Separase
expression in testis and other tissues (mammary gland and ovary,
data not shown) using immunoblot analysis indicated a reduction
in the total Separase protein level in the ESPL1
+/hyp mice,
compared to wild type littermate controls (Figure 1B), indicating a
possible instability of the truncated C-terminal protein. It is also
interesting to note that Separase transcript level in the ESPL1
+/hyp
mice was found to be slightly higher than that in WT mice (data
not shown) again suggesting that an unstable Separase protein
results from insertion of the gene cassette in the hypomorphic
mice, resulting in decrease in protein but not in mRNA levels.
2. Reduction in Separase levels cooperates with loss of
p53 in the formation of T and B cell lymphomas in mice
To examine if a reduction in Separase levels leads to
chromosome missegregation and increases the risk of tumorigen-
esis, survival analysis was performed using littermate cohorts of
Separase heterozygous hypomorphic mice (ESPL1
+/hyp) and
control WT mice in identical C57Bl/6 genetic backgrounds.
Animals were sacrificed when terminally ill or when they reached
the age of 24 months (,2 years). Animals sacrificed at the study
end point were censored in survival data if they did not display
tumor phenotype. However, upon observation of mice maintained
in our colony beyond the time period shown in survival curve
(Figure 2), we found that the ESPL1
+/hyp animals had a longer
mean average tumor-free lifespan (more than 800 days vs. 600
days for WT) compared to that reported for WT C57Bl/6 animals
[37]. As the functional loss of a single allele of ESPL1 occurred in
all tissues, mice were examined for all possible tumor types upon
necropsy. We failed to observe any tumors or any other obvious
abnormalities in the ESPL1
+/hyp mice during their life span though
about 5% of the control cohort of littermate WT mice developed
sarcomas and appeared sick (possible lymphomas) and had to be
sacrificed within a 2 year time frame.
Since the in vivo effects of mitotic checkpoint impairment and
chromosome missegregation are not very well defined, we took
into consideration the possibility that cell cycle checkpoints turned
on by the presence of an active p53 protein might override
tumorigenic effects of the loss of a single allele of ESPL1. That is,
cells lacking Separase that develop chromosomal abnormalities
may be eliminated by p53-dependent checkpoint arrest or
Separase and p53 in Mouse Lymphoma
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+/hyp
animals would be expected to cooperate with reduction of
Separase protein levels in tumorigenesis. Additionally, if loss of
Separase expression increases the rate of chromosomal missegre-
gation in vivo, ESPL1
+/hyp mice on a p53 heterozygous background
should be more likely to experience loss of the wild-type p53 allele
to allow tumors to progress. Loss of heterozygosity of p53 has been
suggested as a possible mechanism and also a rate limiting step in
the development of tumors upon irradiation in p53 heterozygous
mice [38]. To test these hypotheses, survival analysis was
performed on cohorts of ESPL1
+/hyp animals and littermate
controls generated on p53 heterozygous and homozygous
backgrounds. ESPL1
+/hyp, p53
2/2 mice developed aggressive and
widespread lymphomas involving the lung, liver, thymus, bone
marrow and peripheral blood, with a significantly reduced latency
compared to p53
2/2 animals alone (Figure 2, red vs. blue line,
P,0.005, Log Rank Test). Also the ESPL1
+/hyp, p53
+/2 mice
developed carcinomas in various organs, with a significantly
reduced latency compared to the p53 heterozygous mice alone
(P,0.005, Log Rank Test) in a C57BL/6 background. Approx-
imately 86% of the ESPL1
+/hyp, p53
2/2 animals developed
lymphomas with a median survival period of 118 days, compared
to about 37% p53
2/2 animals that developed pathologically
confirmed lymphomas in the same time period. On the other
hand, approximately 50% compound heterozygote (ESPL1
+/hyp,
p53
+/2) animals developed carcinomas over a period of 460 days
(about 14 months), compared to p53
+/2 animals, a much smaller
percentage of which developed a significant tumor phenotype over
Figure 1. Disruption of ESPL1 gene that encodes Separase protein (A) leads to the disruption of the C-terminal peptidase domain of
the Separase protein. Top, schematic of ESPL1 gene mutation by insertion of a gene trap vector, resulting in a truncated Separase protein is
shown. Primer sets P1 and P3 are used to genotype the mice with mutant allele and P1 and P2 are used to genotype mice with the wild type allele.
(B), Western blot analysis of endogenous Separase protein from testis derived from the mutant mice and their wild type littermate controls (as
indicated by the genotypes). (C), Densitometric quantification of Separase expression in the ESPL1
+/hyp mice compared to wild type after
normalization to the expression of a housekeeping gene b-actin to compensate for loading control.
doi:10.1371/journal.pone.0022167.g001
Figure 2. Lymphoma onset and progression are accelerated by Separase reduction. Double mutant (ESPL1
+/hyp,p53
2/2) animals developed
severe lymphomas with a median latency of 118 days and within 200 days all animals developed full blown lymphomas (red line). In p53
2/2 animals
(blue line), lymphomas were detected significantly later (p,0.0001) with a median onset of 151 days and progression of lymphomas was significantly
slower, measured by sick appearance of the mice and subsequent histopathological analysis. The ESPL1
+/hyp, p53
+/2 mice (yellow line) do not develop
lymphomas but develop other phenotypes over a longer period of time.
doi:10.1371/journal.pone.0022167.g002
Separase and p53 in Mouse Lymphoma
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levels of Separase co-operates with the loss of p53 in the initiation
and progression of tumors, with other stochastic changes occurring
along the way to initiate tumor formation. The ESPL1
+/hyp, p53
+/2
and ESPL1
+/hyp, p53
+/+ mice do not develop lymphomas over a
period of 200 days (pre-dominant phenotype in each genotype
summarized in Table 1).
3. Reduction in Separase levels contributes to increased
aggressiveness and metastatic profile of lymphomas in
the ESPL1
+/hyp, p53
2/2 mice
Homozygous p53 null mice (p53
2/2) have been reported to
develop predominantly T cell thymic lymphomas with infrequent
involvement of lymph nodes in multiple organs including liver,
lung and kidney. Crossing the p53
2/2 mice to the ESPL1
+/hyp mice
to generate the ESPL1
+/hyp, p53
2/2 mice significantly altered the
lymphoma profile as well as the latency for lymphoma
development. The double mutant mice developed mixed T and
B cell lymphomas (Figure 3g–i) shown by staining for T and B cell
specific markers B220 and CD3, respectively). In contrast to the
p53
2/2 mice, lymphoma in ESPL1
+/hyp, p53
2/2 were seldom
localized to the thymus, but most commonly infiltrated to the
lungs, liver and spleen. The lungs (Figure 3a), liver (Figure 3b) and
spleen (Figure 3f) in these mice were often completely depleted by
lymphoma cells and normal anatomy of these organs was not
visible. In all these organs very high levels of proliferation was
observed coupled with the presence of homogenous sheets of
atypical round cells and large pleomorphic nuclei. Invasion of
lymphoma cells was also observed less frequently in the colon and
kidney and on the cardiac surface in these mice (data not shown).
Furthermore, the double mutant mice had significant lymphoma
invasion in the bone marrow (Figure 3c) and in the peripheral
blood, as seen by the appearance of blasts in blood smears from
these mice (Figure 3d, 3e, arrow), indicating that they had a
leukemic profile. The percentage of animals displaying each of
these phenotypes is summarized in Table 1. These findings suggest
that the reduction in Separase in the absence of p53 plays a
synergistic role in contributing to the severe phenotype in the
hematopoietic system.
4. Lymphomas in ESPL1
+/hyp, p53
2/2 mice have increased
levels of proliferation and DNA damage
As Separase plays a critical role in the ability of cells to complete
mitosis and go through cell cycle, we checked the levels of
proliferation in the tissues affected by lymphoma (identified by
histological examination) of the ESPL1
+/hyp mice in various p53
backgrounds. To carry out these experiments, tissue sections from
lymphoma invaded lung, liver and thymus in the terminal mice
were stained with the proliferation marker Ki67. We observed that
while normal lungs from wild type age matched litter mate mice
exhibited very low levels of proliferation (exhibited by Ki67
positive staining of cycling cells), the ESPL1
+/hyp p53
2/2 mice
showed a striking increase in proliferation in their lung tissue with
up to 80% cells stained positive for Ki67 (Figure 4A and 4B). The
lymphoma invasion in the lungs in these mice ranged from 20–
50% (as seen by H&E observation of lung sections, Figure 3A),
indicating that possibly both lymphoma as well as lung epithelial
cells contributed to the increase in proliferation. Lung tissue
(Figure 4A, second panel from top) and thymus tissue sections
(data not shown) taken from the p53
2/2 mice that showed
lymphoma invasion in lung and thymus did not show a significant
increase in proliferation above control levels, suggesting that the
cells contributing to lymphomagenesis in the double mutant mice
had a proliferative advantage that could contribute to the
decreased latency in their lymphoma progression.
To further identify causes for the shortened latency and more
aggressive lymphoma development in the double mutant mice and
also to investigate the possible contribution of Separase in vivo in
DNA damage repair [39–46] we examined the level of DNA
damage in various lymphoma affected tissues of these mice. DNA
damage was assayed by staining tissue sections with gamma-
H2AX, a commonly used DNA damage marker and counting cells
stained positive for this marker. We observed that while wild type
age matched littermate mice had very few gamma H2AX positive
cells in their lungs (due to absence of lymphoma cells), the double
mutant mice had a significantly high percentage of cells that
stained positive for gamma-H2AX (Figure 4C and 4D). Up to a
15% increase in DNA damage was detected in the lymphoma
invaded lungs of the double mutant mice. The p53
2/2 mice did
not show a significant rise in DNA damage in their lymphoma
affected tissues compared to the wild type litter mate cohorts.
To further investigate the levels of proliferation and DNA
damage accumulation in pre-neoplastic (not affected by lympho-
ma) tissues in these mice, primary splenocytes and bone marrow
cells from ESPL1
+/hyp, p53
2/2, p53
2/2 and WT mice at the
average age of three months (not affected by lymphoma) were
stained for Ki67 and gamma H2AX markers. The normal
(potentially pre-neoplastic splenocytes and bone marrow cells
obtained from the double mutant (ESPL1
+/hyp, p53
2/2) showed
significantly higher levels of proliferation compared to the p53
2/2
and WT cohorts (Figure S1). However any significant increase in
DNA damage was not observed in any genotype of these primary
bone marrow and splenocytes (data not shown).
5. Aberrant nuclear localization of Separase in Interphase
nuclei of lymphomas co-localizes with DNA damage foci
AsSeparasehasbeenimplicatedinDNAdamagerepairpathways
[19] we checked the levels of Separase protein in the tumor tissues
(identified by histological examination) of the ESPL1
+/hyp mice in
Table 1. Tumor incidences and morphologies displayed by
various ESPL1 and p53 genotypes.
Tumor Type (%) Genotype
ESPL1
+/hyp,
p53
2/2 p53
2/2
ESPL1
+/hyp,
p53
+/2 ESPL1
+/hyp p53
+/2
Lymphoma 100 70 0 0 0
Carcinoma 9 0 40 0 0
Sarcoma 0 50 10 0 0
Lymphoma
Infiltration (%)
Thymus 100 100 0 0 0
Liver 20–80 0 0 0 0
Spleen 80 25 0 0 0
Lung 20–50 5 0 0 0
Kidney 0 0 0 0 0
Colon 2 0 0 0 0
Bone Marrow 30 0 0 0 0
Peripheral Blood 40 0 0 0 0
Since mice from certain genotypes have multiple tumor types and show
lymphoma infiltration in multiple organs, the sum exceeds 100%.
doi:10.1371/journal.pone.0022167.t001
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sections from lymphoma invaded lung, liver and thymus in the
terminal ESPL1
+/hyp,p 5 3
2/2 mice as well as tissues affected by va-
rious carcinomas (colon, mammary and salivary) in the ESPL1
+/hyp,
p53
+/2 mice were stained with Separase antibody. We observed that
while various tissue sections from normal wild type age matched
litter mate mice exhibited very low levels of Separase protein (seen
only in mitotic cells, wild type lung and liver, Figure 5A, bottom two
panels), the ESPL1
+/hyp,p 5 3
2/2 mice showed a striking increase in
interphase nuclear Separase levels in the lymphoma invaded tissue
(Figure 5A, top panel). Tissue sections taken from the carcinomas in
ESPL1
+/hyp,p 5 3
+/2 mice failed to show similar increased nuclear
Separase levels in interphase cells and were comparable to wild type
mouse tissue (Figure 5A, colon carcinoma, second panel). Further-
more, significant co-localization of the nuclear Separase staining in
the lymphomas from ESPL1
+/hyp,p 5 3
2/2 mice was observed with
the DNA damage marker gamma H2AX (Figure 5A, top panel).
The carcinomas and wild type tissue sections had no observable
DNA damage, and Separase staining was only observed in mitotic
cellsinthesetissues(Figure5A,bottomtwopanels).Toascertainthat
Separase was localized to the nuclei of non-mitotic (interphase) cells
in the lymphomas derived from the ESPL1
+/hyp,p 5 3
2/2 mice, co-
staining was performed with Separase antibody and a anti-Phospho
Histone H3(Ser 10)antibodyasa mitoticmarker(Figure5B,bottom
panel). A fraction of cells inthe lymphoma invaded lungs werefound
to stain for Separase alone and not for anti-PH3, whereas in normal
lung tissue, Separase staining was only observed in anti-PH3 positive
(mitotic) cells (Figure 5B, top panel).
6. Reduction in levels of p53 and Separase co-operate in
tumor progression
The protein level in the ESPL1
+/hyp, p53
+/2 was comparable to
the ESPL1
+/hyp animals, but lower then WT animals (see Figure
S2). To assess if there was a selective pressure for the loss of the
wild type allele of ESPL1 during lymphoma progression in mice,
real-time quantitative PCR analysis was employed to determine
the status of the wild-type ESPL1 allele in ESPL1
+/hyp, p53
2/2 and
ESPL1
+/hyp, p53
+/2 tumors. Our analysis showed a significant
reduction in Separase transcript levels in carcinomas compared
to matched normal tissues in the ESPL1
+/hyp, p53
+/2 mice
(Figure 6A). Reduction in Separase transcript levels was also
Figure 3. ESPL1
+/hyp, p53
2/2 mice develop widely disseminated lymphoma and leukemia involving the lung, liver, spleen, bone
marrow and peripheral blood. Hemotoxylin and eosin staining of ESPL1
+/hyp, p53
2/2 mice lymphoma affected tissue sections shows that the
terminal stage lymphomas have varied morphologies. Poorly differentiated and homogenous populations of atypical round lymphocyte cells were
observed in the lung alveoli (a, arrow) showing acute lymphoma invasion in the lungs. The liver tissues in these mice (b) were depleted by atypical
lymphocytes and homogenous round cells with frequent large pleomorphic nuclei infiltrating between the hepatic cores and sinusoids (b, arrow).
Invasion of lymphoma was observed in the bone marrow (c, arrow) and presence of blast cells suggested leukemic infiltration in the peripheral
blood (d, e, arrows). Frequent invasion of lymphoma was also observed in the spleen (f) resulting in complete loss of normal spleen morphology.
Both B cell positive (g, brown stain, arrow, B220 positive) and T cell positive (h and i, brown stain, arrow, CD3 positive) lymphoma cells were observed
in these lymphomas. Percentages of tumor types displayed in the various genotypes are tabulated in Table 1. Scale bar=50 mm.
doi:10.1371/journal.pone.0022167.g003
Separase and p53 in Mouse Lymphoma
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+/hyp, p53
2/2
mice compared to wild type mouse tissue (Figure 6A). Further-
more, to assess the role of p53 in the progression of carcinomas in
the ESPL1
+/hyp, p53
+/2 mice, we analyzed tumor and matched
normal tissue (taken from the area surrounding the tumor) from
these mice (Figure 6B). A significant reduction in p53 transcript
Figure 4. ESPL1
+/hyp, p53
2/2 mice show increased proliferation and DNA damage in the lungs. Lungs from WT, p53
2/2, ESPL1
+/hyp, p53
+/2
and ESPL1
+/hyp, p53
2/2 mice were analyzed for cellular proliferation. Only lung tissue from p53
2/2 and ESPL1
+/hyp, p53
2/2 mice showed lymphoma
invasion and lung tissue from WT and ESPL1
+/hyp, p53
+/2 were normal. Proliferation levels are indicated by the percentage of cells in any cycling phase
of the cell cycle (G1, S, G2, M) (B) calculated by counting Ki67 cells (red) as a percentage of total cells (DAPI, blue) as shown in (A) (n=at least two
mice for each genotype were used and for each genotype 5 microscope fields and.500 cells were counted.). Each bar represents an individual
mouse for that genotype. Significant difference was observed between proliferation levels in the lymphoma invaded lungs of the ESPL1
+/hyp; p53
2/2
mice compared to all other cohorts (P=0.01). Estimated percentage lymphoma invasion in lungs of mice from each genotype is shown in B. Lungs
from WT, p53
2/2, ESPL1
+/hyp, p53
+/2 and ESPL1
+/hyp, p53
2/2 mice were analyzed for DNA damage. DNA damage levels are indicated by the percentage
of cells stained positive for cH2AX (D) calculated by counting cells showing detectable levels of cH2AX foci (red) as a percentage of total cells (DAPI,
blue) as shown in (C). Significant difference was observed between DNA damage foci levels in the ESPL1
+/hyp, p53
2/2 mice compared to all other
cohorts (P=0.005). Scale bar=20 mm.
doi:10.1371/journal.pone.0022167.g004
Separase and p53 in Mouse Lymphoma
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as well as tissue surrounding the tumor (tumor microenvironment)
(P=0.0001) taken from the ESPL1
+/hyp p53
+/2 mice, suggesting
that loss of p53 function in the tumor tissue itself as well as tumor
microenvironment was a rate limiting step in the progression of
these tumors. Tissue from ESPL1
+/hyp p53
2/2 mice was used as a
control for p53 transcript levels.
7. Reduced Separase levels promote aneuploidy in
p53
2/2 mice
To determine if altered Separase expression co-operates with
loss of p53 in lymphoma progression by accumulating aneuploidy,
we performed metaphase spread counts on splenocytes and bone
marrow cells isolated from wild type, p53
2/2 and ESPL1
+/hyp,
p53
2/2 mice (Figure 7A–F). Primary splenocytes and bone
marrow cells were sampled from normal tumor-free mice of all
three genotypes, at multiple ages (time points) to detect pre-
malignant changes in chromosome numbers if any. Metaphase
spread counts revealed a significant increase in abnormal
chromosome numbers (both gain and loss, tabulated in Table 2)
in the double mutant mice compared to p53
2/2 mice alone.
Accumulation of aneuploidy was detected in splenocytes in the
double mutant (ESPL1
+/hyp, p53
2/2) mice as early as by 2.5
months of age (Figure 7D). Further analysis of normal (lymphoma
free) splenocytes from four month old ESPL1
+/hyp, p53
2/2 mice by
SKY analysis revealed widespread and clonal chromosomal
changes with a composite karyotype 36–70, XY, +3, +12, +14,
+15, +19[cp6]/40, XY [15], showing gains in chromosomes 3, 12,
Figure 5. Lymphomas in ESPL1
+/hyp, p53
2/2 mice have increased nuclear localization of Separase protein that co-localizes with DNA
damage foci. Tumor sections from ESPL1
+/hyp, p53
2/2 (A, lung invaded with lymphoma, top panel) and ESPL1
+/hyp, p53
+/2 (A, colon carcinoma,
middle panel) and WT (A, normal lung, third panel, normal liver, bottom panel) mice were co-stained with Separase and gamma H2AX
antibodies. A significant increase in nuclear co-localization of Separase and gamma H2AX was observed in the lymphoma tissue from the ESPL1
+/hyp,
p53
2/2 mice compared to matched normal tissues and carcinomas taken from the ESPL1
+/hyp, p53
+/2 and p53
2/2 mice. Carcinomas from the
ESPL1
+/hyp, p53
+/2 showed insignificant levels of gamma H2AX staining comparable to wild type tissue and nuclear Separase was only seen in mitotic
cells in these genotypes. (Separase=Green, cH2AX=Red). Separase localization in interphase nuclei (non-mitotic cells) was observed in the
lymphoma invaded lung tissue when co-stained with a mitotic cell marker (anti- phospho histone H3 (Ser 10), Panel B, bottom). In normal lung, co-
localization of Separase and PH3 was only seen in mitotic cells (Panel B, top). (Separase=Green, PH3=Red). Scale bar=10 mm.
doi:10.1371/journal.pone.0022167.g005
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shown in Figure 7G). Similar chromosomal changes were not
noted in splenocytes isolated from age matched p53
2/2 mice.
Discussion
Since its discovery in yeast as an important cell cycle component
that holds sister chromatids together [47,48], the cohesin proteins
have been the focus of intense research. The role of loss of
components of the cohesin complex in generating genetic
instability [3,49], DNA damage repair defects [39–46] as well as
alterations in gene expression [50–53] have been studied in cell
culture systems. Several studies have reported loss or gain of
specific components of the cohesin complex, suggesting correlation
between cancer initiation and/or progression and the expression
and function of these proteins. Specifically recent evidence in
multiple genetically unstable human cancers [54] have brought
into speculation the possible role of cohesin protein defects in
promoting aneuploidy that may play a causal role in tumorigen-
esis. However, in vivo models to study the effect of gain or loss of
individual components of the cohesin complex in tumor
development are currently lacking. Here we present evidence that
reduction in cohesin protease, Separase in mice collaborates with
p53 inactivation in the genesis and progression of aggressive B-
and T-cell lymphoma and leukemia in mice. We show that the
spectrum of lymphomas in these mice are completely different
from those observed in p53 null mice alone and involve the spleen,
lung and liver as well as bone marrow, but not the thymus. Our
studies also demonstrate that lymphoma formation in the double
mutant (ESPL1
+/hyp, p53
2/2) mice is greatly accelerated by
Figure 6. Q-PCR analysis of lymphomas and carcinomas arising in the ESPL1
+/hyp mice in varying p53 backgrounds reveals
significant reduction of p53 and Separase mRNA levels. Separase and p53 transcripts in various tumor tissues was compared across different
mouse genotypes to matched wild type litter mate mouse tissue. (A) A comparison of the relative Separase mRNA expression levels in wild type and
ESPL1 mutant mice in a C57BL/6 background indicates a significant reduction in Separase expression levels both in the ESPL1
+/hyp, p53
2/2 lymphoma
tissue (P=0.0003) as well as in the carcinomas from the ESPL1
+/hyp, p53
+/2 mice (P=0.007). (B) Relative mRNA expression levels of p53 in wild type
and mutant mice in a C57BL/6 background are shown. Tissue taken from both tumor microenvironment and tumor tissue from the same ESPL1
+/hyp,
p53
+/2 mice show a significant reduction in p53 transcript levels compared to levels of p53 in wild type mice tissue (P=0.003 and P=0.004
respectively). RNA isolated from ESPL1
+/hyp, p53
2/2 mice lymphomas was used as a control for p53 transcript levels. (‘n’ denotes number of tumors
and red star denotes significant difference compared to wild type tissue).
doi:10.1371/journal.pone.0022167.g006
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+/hyp, p53
2/2 primary splenocytes display increased aneuploidy. Distribution of chromosome numbers in the three
genotypes are shown here (A, Wild Type; B, C p53
2/2, D, E, F, ESPL1
+/hyp, p53
2/2). Average counts from splenocytes of two normal mice (tumor free)
per genotype, (average age 4 months for wild type, 4 and 5 months for p53
2/2 mice and 2.5, 4 and 5 months for ESPL1
+/hyp, p53
2/2 mice) was
plotted. At least 50 metaphases were counted per genotype. A representative SKY image (G) of splenocytes of a 4 month old ESPL1
+/hyp, p53
2/2
mouse shows gains in chromosomes 15, 19 and Y (the change in Y chromosome number seen here is not clonal).
doi:10.1371/journal.pone.0022167.g007
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early in these mice. We provide a mouse model for further
understanding the biology and pathways disrupted in human
lymphoma and leukemia.
Separase hypomorphism co-operates with loss of p53 to
promote a more aggressive lymphoma phenotype
compared to p53 loss alone
Separase is an essential protein. Previous studies indicated that
conditional depletion of Separase in mouse bone marrow causes
aplasia and apparent death of hematopoietic cells other than
erythrocytes [21]. Our model suggests that optimal levels of
Separase acts as a tumor suppressor in the absence of p53 and that
loss of Separase and p53 effectively synergize the lymphoma and
leukemia formation. While loss of p53 alone results primarily in
localized thymic T cell lymphomas, as has been reported before
[31], the combined reduction of Separase with loss of p53 results
in more widespread B- and T-Cell lymphoma and leukemia with
gross involvement of the bone marrow. Direct synergy between
p53 loss and Separase reduction is clearly demonstrated by the
accelerated tumor development in ESPL1
+/hyp, p53
2/2 mice
compared to p53
2/2 (ESPL1 WT) animals. Surprisingly, reduction
in Separase levels alone does not lead to tumorigenesis, suggesting
that very low levels of Separase within the cell may be sufficient to
provide the enzymatic activity to cleave Rad21 and prevent
chromosomal missegregation. Also, downstream anti-proliferative
and pro-apoptotic effects of a functional p53 most likely prevent
the accumulation of defects to lead to lymphomagenesis in these
mice.
We show here that both the combined inactivation of Separase
and p53 as well as a reduction in p53 gene dosage contributes to
tumorigenesis. The reduced levels of Separase expression in only
some but not all the lymphomas arising in the ESPL1
+/hyp, p53
2/2
mice suggesting that in a tumor microenvironment, complete loss
of Separase is a stochastic but non-essential event. Furthermore,
spleen tissue from ESPL1
+/hyp, p53
2/2 mice have high accumu-
lation of genomic instability and aneuploidy as early as in 2.5
month old mice, indicative of the critical role of Separase in
maintenance of genomic stability. In contrary, the double
heterozygous mice (ESPL1
+/hyp, p53
+/2) develop tumors over a
longer time, most likely resulting in the gradual accumulation of
stochastic events. We have previously reported [14,15] that over-
expression of Separase results in the premature separation of sister
chromatids leading to aneuploidy in the mammary epithelium,
thus suggesting that optimal levels of Separase is required for the
maintenance of a tumor free cellular milieu. We show here that
Separase can potentially act as an oncogene or as a tumor
suppressor, and its role depends on its level of expression and tissue
type. Manipulation of Separase level may therefore, contribute
towards the development of a novel therapy to target aneuploid
tumors. Of interest is also the fact that the Separase mutant mice
alone (ESPL1
+/hyp) do not have a lymphoma phenotype. This may
suggest that though loss of Separase is a predisposing condition for
hematopoietic malignancy, the further progression of cancer is
blocked by apoptotic and other cell death pathways induced by an
active p53.
It is a well recognized concept now that more than one
biological pathway needs to be deregulated in order to transform
normal cells into malignant tumor cells [55]. Loss of p53 results in
loss of apoptotic responses and cell cycle control. This is sufficient
to develop thymic lymphomas that do not involve the bone
marrow and are hence less aggressive in nature. Loss of Separase
in the p53 null mice results in the accumulation of aneuploidy
leading to the quickened progression of the disease as well as its
heightened malignancy, involving widespread leukemia in the
bone marrow.
Combined loss of Separase and p53 promotes
aneuploidy
In vivo studies in the mouse mammary epithelium have shown
that over expression of Separase results in the development of
gross aneuploidy suggesting an important aneuploidy promoting
role of Separase [14,56]. We show here that functional loss of
single allele of ESPL1 in the absence of p53 is also sufficient to
induce significant levels of aneuploidy in normal cells in vivo,a s
indicated by the abnormal metaphase counts and SKY analysis of
primary splenocytes isolated from ESPL1
+/hyp, p53
2/2 mice. The
accumulation of these genetic abnormalities in these mice may also
account for the increased DNA damage levels identified in the
lymphomas that infiltrated the lungs and liver of these mice.
The accumulation of gross genomic instability as well as DNA
damage in the absence of p53 induced apoptosis could be a
mechanism that aids the quicker lymphomagenesis in the double
mutant mice. Lymphocytes are rapidly proliferating cells that have
a very quick turn over time and require extensive and efficient
DNA damage repair. Separase has been implicated in having a
role in DNA damage repair [19]. This is thought to happen by the
Separase-mediated cleavage of Rad21 and the removal of the
cohesin complex from the site of DNA double strand breaks,
allowing repair factors to approach the DNA and facilitate repair.
It has also been suggested that the release of Separase by Securin
to allow cohesin cleavage during DNA damage repair is a p53
mediated process [57]. However, direct in vivo evidence of the role
of Separase in DNA damage repair in higher eukaryotes is still
lacking. We show here that reduced levels of Separase in the
absence of p53 plays an important role in the accumulation of
genomic instability in lymphocytes, possibly allowing the accumu-
lation of gross chromosomal abnormalities as well as DNA damage
finally resulting in acute lymphoma and leukemia development.
Also important is the observation that ESPL1
+/hyp mice alone in
the presence of an active p53 do not develop lymphomas and also
have a longer tumor-free life span compared to wild type mice,
possibly suggesting that increased levels of apoptosis and p53
Table 2. Analysis of aneuploidy in normal (tumor free)
splenocytes and bone marrow cultures.
Genotype Tissue % Aneuploidy
WT (1) Spleen 0
Bone Marrow 0
WT(2) Spleen 2
Bone Marrow 0
p53
2/2 (1) Spleen 26
Bone Marrow Not available
p53
2/2 (2) Spleen 23
Bone Marrow Not available
ESPL1
+/hyp, p53
2/2 (1) Spleen 59
Bone Marrow 81
ESPL1
+/hyp, p53
2/2 (2) Spleen 55
Bone Marrow 88
Values are from two independent mice (average age=4 months) for each
genotype. At least 50 metaphase spreads were counted for each culture. (1 and
2 represent two individual mice).
doi:10.1371/journal.pone.0022167.t002
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lation of genetic instability and DNA damage accumulation and
prevent cancer progression in these mice.
Loss of Separase causes a phenotypic change from
‘‘localized’’ thymic lymphoma to diffuse lymphoma and
leukemia involving multiple organs, peripheral blood and
bone marrow
Human lymphoma and leukemia have various subtypes
indicating the involvement of many different cell lineages in its
initiation and progression. In our model, lymphomas that
developed in the p53
2/2 mice alone were restricted to the thymus
with occasional involvement of the lymph nodes in the lung and
liver. Histopathological analysis indicated no bone marrow
involvement in these animals. However, the combined reduction
of Separase levels with loss of p53 changed the lymphoma
spectrum in these mice to a more widely disseminated phenotype,
involving lymph nodes of the lung, liver, thymus and spleen and
also showing gross bone marrow involvement. It is conceivable
that reduction of Separase levels along with loss of p53 results in
the accumulation of DNA damage and aneuploidy in an
independent subset of hematopoietic cells (from those affected by
loss of p53 alone), resulting in the appearance of a more
widespread T- and B-cell lymphoma phenotype as well as bone
marrow involvement. Understanding of the specific hematopoietic
subsets in this model will require further investigation with the use
of cell lineage specific markers.
In summary, ESPL1
+/hyp, p53
2/2 mice provide a new animal
model for aggressive lymphoma not only to study the mechanism
of lymphoma development but also for preclinical evaluation of
new agents for lymphoma therapy.
Materials and Methods
Transgenic animals
mESPL1 gene-trapped ES cell clone (XL058) was obtained from
Bay Genomics (San Francisco, CA). The gene trap is produced by
a splice-acceptor-b-geo cassette within Espl1 exon 30 deleting the
C-terminal 105 amino acid, a critical portion of its peptidase
domain. The ES cells were injected into 129/SV blastocysts, and
resulting chimeras were crossed to C57Bl/6J females and screened
for germline transmission by PCR. Animals used in experiments
reported here were backcrossed at least ten generations to the
C57Bl/6J background. The p53 mice were obtained from Jackson
Labs in a C57BL6 strain. All animal experiments were approved
by the Institutional Animal Care and Use Committee (IACUC) of
the Baylor College of Medicine. All animal studies were carried
out in strict compliance with federal and local guidelines for
animal care and use.
Immunoblotting
Mouse tissues were flash frozen in liquid nitrogen and stored at
280uC. Proteins were extracted in lysis buffer and quantified and
Western Blot analysis performed as reported before [14]. Mem-
branes were probed with anti mouse Separase monoclonal antibody
(Abnova, Taipei, Taiwan; 1:500), raised against the N terminal
domain of Separase. The specificity of this antibody on mouse
Separase was tested before by [16]. Equal loading was verified using
a mouse monoclonal anti-ß-actin antibody (Sigma, St. Louis, MO).
Survival and tumorigenesis analysis
Animals were monitored regularly for signs of illness up to the
age of 2 years. Overall and tumor-free survival times and P values
were determined by Kaplan-Meier and Wilcoxon’s log rank
analyses (P values are shown for comparison). Animals that were
tumor free at necropsy were censored in the survival analyses.
Animals that died of unknown causes were also censored in
lymphoma-free survival analysis but not in overall survival
analyses. Lymphoma diagnoses were based on histological
confirmation of tumors. Comparison of tumor frequencies was
done by Fisher’s exact test with one-tailed P values. All statistical
analyses were performed with Graph Pad Prizm software
(GraphPad Software, La Jolla, CA).
DNA damage assay
DNA damage assays were performed using specific anti mouse-
H2AX (Millipore) and anti-rabbit Phospho Serine H2AX antibod-
ies (Cell Signaling Technologies, Danvers, MA). Mitotic marker
anti-Phospho Histone H3 (Ser 10) was used (1:1000, Millipore,
Catalogue # 06-570) to detect mitotic cells.
Immunohistochemistry, metaphase spread and
splenocytes and bone marrow cultures
All IHC and IF analysis was performed using previously
published methods [16]. Metaphase spread from splenocytes and
bone marrow cultures was performed based on previously reported
techniques in [58].
Quantitative PCR
Total RNA was extracted from mouse tissues by grinding the
tissues in liquid nitrogen followed by Trizol (Invitrogen, Carlsbad,
CA) RNA extraction. cDNA was synthesized by reverse transcrip-
tion of mRNA using oligo-dT primers (Invitrogen, Carlsbad, CA)
and Superscript II reverse transcriptase (Invitrogen) as instructed by
the manufacturer. Quantitative real-time PCR was performed with
the Eppendorf Mastercycler Realplex4 system. Custom oligos for
mouse p53 (Forward: GCCATGGCCATCTACAAGAA, Reverse:
ATCGGAGCAGCGCTCATG) and mouse ESPL1 (Forward:
GACCGTGACATTGACCGTTA, Reverse: TAGGCCGTAG-
GCTACAGGTG) were used for amplification. GAPDH (Forward:
TGCACCACCAACTGCTTAGC, Reverse: GGCATGGACT-
GTGGTCATGAG) was selected for normalization.
Spectral Karyotyping (SKY)
The cocktail of mouse chromosome paints was obtained from
Applied Spectral Imaging (ASI, Vista, CA). Hybridization and
detection were carried out according to the manufacturer’s
protocol, with slight modifications. Chromosomes were counter-
stained with DAPI. Images were acquired with a SD300H Spectra
cube (ASI) mounted on a Zeiss Axioplan II microscope using a
custom designed optical filter (SKY-1) (Chroma Technology,
Brattleboro, VT), and analyzed using SKY View 2.1.1 software
(ASI, Vista, CA) [59].
Statistical Analysis
For the histological analysis a ratio of positively stained cell
counts versus total cell counts was computed for each treatment
and each genotype. The staining ratios within each genotype may
not be independent. As such, an average of ratios was computed
for each mouse genotype. The statistical significance of differences
in mean genotype ratios between treatments were evaluated using
two-tailed unequal variance Student’s t-tests.
Supporting Information
Figure S1 ESPL1
+/hyp, p53
2/2 mice show increased
proliferation in normal splenocytes isolated from 3
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p53
2/2 and ESPL1
+/hyp, p53
2/2 mice were analyzed for cellular
proliferation. Proliferation levels are indicated by the percentage of
cells in any cycling phase of the cell cycle (G1, S, G2, M) (B)
calculated by counting Ki67 cells (red) as a percentage of total cells
(DAPI, blue). (n=at least two mice for each genotype were used
and for each genotype 5 microscope fields, 60X magnification
and.500 cells were counted). The average counts for both mice in
each genotype were plotted. Significant difference was observed in
proliferation levels in the ESPL1
+/hyp; p53
2/2 compared to all
other cohorts (P=0.01).
(TIF)
Figure S2 Western blot analysis of endogenous Separ-
ase protein from testis derived from the ESPL1
+/hyp mice
in p53 heterozygous and homozygous backgrounds show
lower level of Separase compared to wild type mice.
Western blot from testis tissue of mutant mice and their wild type
littermate controls (as indicated by the genotypes) is shown (top).
Densitometric quantification of Separase expression in the
ESPL1
+/hyp mice in p53 heterozygous and homozygous back-
grounds compared to wild type after normalization to the
expression of a housekeeping gene c tubulin to compensate for
loading control (bottom).
(TIF)
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